Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer

被引:0
|
作者
Xuefeng Zhou
Jianjun Wang
Jiashun Wang
Yongcheng Pan
Jingsong Li
Wendong Wang
Feng Zhao
机构
[1] Huazhong University of Science and Technology,Department of Thoracic Surgery, Union Hospital, Tongji Medical College
关键词
non-small cell lung cancer; neo-adjuvant therapy; surgery; prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
In order to explore the possibility to predict the risk factors for postoperative complications and survival time, the clinical data of 152 patients (including 116 males and 36 females) who had undergone neo-adjuvant therapy and surgery for stage IIIA and B non-small cell lung cancer (NSCLC) were retrospectively analyzed. Demographic data, preoperative functional parameters, staging, induction regimen (chemotherapy alone or associated with radiotherapy), associated disorders, and data about operation were collected. Chi-square test and multivariate analysis fitting the unconditional logistic regression model were performed to identify predictors of postoperative complications, while Kaplan-Meier and multivariate Cox proportional hazard model were employed to identify predictors of survival time, respectively. The univariate analysis demonstrated that forced expiratory volume in 1 second predicted percent (FEV1%, P=0.040) and associated disorders (P=0.020) were the predictive factors of complications, but multivariate analysis found no independence factors (P>0.05) of it. Univariate Kaplan-Meier analysis showed that stage (P=0.050) and pneumonectomy (P=0.018) affected the survival time. However, multivariate Cox proportional hazard model analysis demonstrated that only pneumonectomy (P=0.026) was associated with a decreased survival time, but no differences between right and left pneumonectomy were found. The results suggest that the risk factor for postoperative complications is acceptable, and pneumonectomy is associated with increased mortality, which should be performed only in stage III NSCLC patients.
引用
收藏
页码:677 / 680
页数:3
相关论文
共 50 条
  • [1] Analysis of Prognostic Factors for Surgery after Neo-adjuvant Therapy for Stage III Non-small Cell Lung Cancer
    Zhou, Xuefeng
    Wang, Jianjun
    Wang, Jiashun
    Pan, Yongcheng
    Li, Jingsong
    Wang, Wendong
    Zhao, Feng
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2008, 28 (06) : 677 - 680
  • [2] Neo-adjuvant chemotherapy in early stage non-small cell lung cancer
    Boukovinas, Ioannis
    Tsakiridis, Kosmas
    Zarogoulidis, Paul
    Machairiotis, Nikolaos
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Zarogoulidis, Kostantinos
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S446 - S448
  • [3] Non-small cell lung cancer: Adjuvant and neo-adjuvant chemotherapy
    Brahmer, Julie R.
    Ettinger, David S.
    RESPIROLOGY, 2007, 12 (03) : 320 - 325
  • [4] Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    Santo, A.
    Genestreti, G.
    Sava, T.
    Manno, P.
    Terzi, A.
    Molino, A. M.
    Cetto, G. L.
    ANNALS OF ONCOLOGY, 2006, 17 : V55 - V61
  • [5] Repeat mediastinoscopy after neo-adjuvant chemotherapy in stage III (N-2) non-small cell lung cancer (NSCLC)?
    Maesen, B
    Snijder, R
    Elbers, J
    delaRiviere, AB
    Schramel, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1052 - 1052
  • [6] Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study
    Mattson, K
    Abratt, R
    Ten, GV
    Krofta, K
    Tonelli, D
    Avril, I
    LUNG CANCER, 2001, 34 : S21 - S23
  • [7] The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy
    Felip, E.
    Vilar, E.
    ANNALS OF ONCOLOGY, 2006, 17 : X108 - X112
  • [8] Neo-adjuvant chemotherapy in early stages of non-small cell lung cancer
    Crinò, L
    LUNG CANCER, 2002, 38 : S31 - S32
  • [9] Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements
    Takenaka, Masaru
    Kuroda, Koji
    Tanaka, Fumihiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 215 - 228
  • [10] Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC)
    Depierre, A
    Milleron, B
    Moro, D
    Quoix, E
    Lebeau, B
    Chastang, C
    Braun, D
    Janicot, H
    Paillot, N
    Gouva, S
    Coudert, B
    Breton, JL
    Lemarie, E
    Lebas, FX
    Coetmeur, D
    Thiberville, L
    Brehot, JM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1053 - 1053